Alx Oncology Holdings (ALXO) Other Operating Expenses (2019 - 2026)

Alx Oncology Holdings (ALXO) posted Other Operating Expenses of $3.2 million for Q2 2025, up 562.84% sequentially from $479000.0 in Q2 2020.

Analysis

Alx Oncology Holdings (ALXO) Other Operating Expenses (2019 - 2026) Analysis & Trends

Alx Oncology Holdings has reported Other Operating Expenses for 3 years, with the latest figure at $3.2 million in Q2 2025.

Quarterly Other Operating Expenses changed N/A year-over-year to $3.2 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $3.2 million (changed N/A YoY) and the FY2025 annual result came in at $3.2 million, changed N/A from the prior year.
Other Operating Expenses advanced to $3.2 million in Q2 2025 per ALXO's latest filing, from $479000.0 in the prior quarter.
Over five years, Other Operating Expenses peaked at $3.2 million in Q2 2025 and troughed at $3.2 million in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.62 Bn	131.77 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.73 Bn	77.73 Bn	3.93 Bn
3	Argenx Se	63.53 Bn	58.35 Bn	1.37 Bn
4	Moderna	58.23 Bn	53.09 Bn	52.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-
6	BeOne Medicines	40.03 Bn	34.93 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.50 Bn	32.19 Bn	992.69 Mn
8	Royalty Pharma	28.52 Bn	27.68 Bn	-
9	Insmed	27.46 Bn	26.30 Bn	358.27 Mn
10	Alx Oncology Holdings	274.67 Mn	274.67 Mn	-

Historic Data

Download Data